Posted by Michael Wonder on 19 Oct 2015
Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival
19 October 2015 - This review of approvals of cancer drugs based on a surrogate end point by the US Food and Drug Administration assesses the postmarketing findings for overall survival.
For more details, go to: http://archinte.jamanetwork.com/article.aspx?articleID=2463590&utm_source=Silverchair%20Information%20Systems&utm_medium=email&utm_campaign=ArchivesofInternalMedicine%3AOnlineFirst10%2F19%2F2015
